Bupropion: Pharmacological and clinical profile in smoking cessation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 2, 2003, Pages 56-66

  Haustein, K O ^a  

^a Inst of Nicotine Res/Smoking Cess   (Germany)

Author keywords

Bupropion (amfebutamone); Clinical trials; Pharmacology; Risk benefit ratio; Side effects; Smoking cessation

Indexed keywords

AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); AMINOALCOHOL; AMINOKETONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR; CIMETIDINE; DESIPRAMINE; DIAZEPAM; DOPAMINE; FLECAINIDE; IMIPRAMINE; INSULIN; MIRTAZAPINE; NICOTINE; NORADRENALIN; PHENYTOIN; PROPAFENONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ADULT; ALLERGIC REACTION; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DOPAMINE UPTAKE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; EOSINOPHILIA; EUPHORIA; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSOMNIA; LIVER TOXICITY; LONG TERM CARE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NICOTINE REPLACEMENT THERAPY; PERIPHERAL NEUROPATHY; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SKIN TOXICITY; SMOKING CESSATION; TASTE DISORDER; TINNITUS; TRANSDERMAL PATCH; VISUAL DISORDER; XEROSTOMIA;

EID: 0037321740     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41056     Document Type: Review

References (84)

1. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS 2002 Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 288: 468-474
2. Anonymus 1996 The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA 275: 1270-1280
3. Anonymus 2000a A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 283: 3244-3254
4. Anonymus 2000b Bupropion (Zyban, sustained-release tablets): update 2000. Can ADR Newsletter 10: 3-5
5. Anonymus 2001a Zyban, bupropion hydrochloride, 150 mg sustained-release tablets. GlaxoSmithKline Greenville NC, 1 - 23
6. Anonymus 2001b Todesfälle in Verbindung mit Raucherentwöhnungsmittel Zyban. http://de.news.yahoo.com/ 0110911/12/ly1or.html.
7. Arzneimittelkommission der deutschen Ärzteschaft 2001 Empfehlungen zur Therapie der Tabakabhängigkeit. Completely printed in: Suchtmed 3: 156-175
8. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E 1995 Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56: 395-401
9. Carrillo-Jimenez R, Zogby M, Treadwell TL 2001 Erythema multiforme associated with bupropion use. Arch Intern Med 161: 1556
10. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al 2002 Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63: 357-366
11. Croft H, Houser TL, Jamerson BD, Leadbetter R, Bolden-Watson C, Donahue R, Metz A 2002 Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther 24: 662-672
12. Dager SR, Heritch AJ 1990 A case of bupropion-associated delirium. J Clin Psychiatry 51: 307-308
13. Dale LC, Glover ED, Sachs DP, Schroeder DR, Offord KP, Croghan IT, Hurt RD 2001 Bupropion for smoking cessation: predictors of successful outcome. Chest 119: 1357-1364
14. David D, Esquenazi J 1999 Rhabdomyolysis associated with bupropion treatment. J Clin Psychopharmacol 19: 185-186
15. Davidson J 1989 Seizures and bupropion: a review. J Clin Psychiatry 50: 256-261
16. Davis JS, Boyle MJ, Hannaford R, Watson A 2001 Bupropion and serum sickness-like reaction. Med J Aust 174: 479-480
17. De Vane CL, Laizure SC, Stewart JT, Kolts BE, Ryerson EG, Miller RL, Lai AA 1990 Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 10: 328-332
18. Dobson R 2001 Antismoking drugs comes under scrutiny after deaths. Br Med J 322: 452
19. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA 1998 A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 59: 366-373
20. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM 2000 Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28: 1222-1230
21. Ferris RM, Cooper BR, Maxwell RA 1983 Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry 44: 74-78
22. Findlay JW, Van Wyck FJ, Smith PG, Butz RF, Hinton ML, Blum MR, Schroeder DH 1981 Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 21: 127-135
23. Fiore MC 2000 US Public Health Service clinical practice guideline: treating tobacco use and dependence. Respir Care 45: 1200-1262
24. Fryer JD, Lukas RJ 1999 Non-competitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288: 88-92
25. GlaxoSmithKline PLC 2001 Antiraucherpille verursacht evtl. Todesfälle. http://de.biz.yahoo.com/010427/85/1k8sp.html.
26. Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, Herrero LA, Krishen A, Sweeney A, Buaron K, Metz A 2001 Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 69: 438-444
27. Goren JL, Levin GM 2000 Mania with bupropion: a dose-related phenomenon? Ann Pharmacother 34: 619-621
28. Griffith JD, Carranza J, Griffith C, Miller LL 1983 Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 44: 206-208
29. Harris CR, Gualtieri J, Stark G 1997 Fatal bupropion overdose. J Toxicol Clin Toxicol 35: 321-324
30. Haustein KO 2000 Pharmacotherapy of nicotine dependence. Int J Clin Pharmacol Ther 38: 273-290
31. Hayes PE, Kristoff CA 1986 Adverse reactions to five new antidepressants. Clin Pharm 5: 471-480
32. Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Glover ED, Sachs DP, Hurt RD 1999 Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 174: 173-178
33. Hays JT, Hurt RD, Wolter TD, Buist AS, Niaura R, Rigotti N, Sachs DPL 2000 Bupropion-SR for relapse prevention. Nicotine Tobacco Res 2: 295-296
34. Hays JT 2000 Tobacco dependence treatment in patients with heart and lung disease: implications for intervention and review of pharmacological therapy. J Cardiopulm Rehab 20: 215-223
35. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD 2001 Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med 135: 423-433
36. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ 2000 CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28: 1176-1183
37. Hesse LM, von Moltke LL, Shader RL, Greenblatt DJ 2001 Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 29: 100-102
38. Holm KJ, Spencer CM 2000 Bupropion: a review of its use in the management of smoking cessation. Drugs 59: 1007-1024
39. Horne RL, Ferguson JM, Pope HG Jr, Hudson JI, Lineberry CG, Ascher J, Cato A 1988 Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 49: 262-266
40. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA 1997 Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus non-smokers. J Clin Pharmacol 37: 737-743
41. Hu KQ, Tiyyagura L, Kanel G, Redeker AG 2000 Acute hepatitis induced by bupropion. Dig Dis Sci 45: 1872-1873
42. Hughes JR, Goldstein MG, Hurt RD, Shiffman S 1999 Recent advances in the pharmacotherapy of smoking. JAMA 281: 72-76
43. Humma LM, Swims MP 1999 Bupropion mimics a transient ischemic attack. Ann Pharmacother 33: 305-307
44. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC et al 1997 A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337: 1195-1202
45. Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J 2001 Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tobacco Res 3: 131-140
46. Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, Feighner JP, Stark P 1991 A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 52: 450-456
47. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al 1999 A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340: 685-691
48. Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS et al 1995 Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 15: 327-333
49. Labbate LA 1998 Bupropion-SR-induced increased libido and spontaneous orgasm. Can J Psychiatry 43: 644-645
50. Laizure SC, DeVane CL, Stewart JT, Dommisse CS, Lai AA 1985 Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 38: 586-589
51. Lindblom N, De Villiers SH, Kalayanov G, Gordon S, Johansson AM, Svensson TH 2002 Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 69: 254-260
52. Lineberry TW, Peters GE Jr, Bostwick JM 2001 Bupropion-induced erythema multiforme. Mayo Clin Proc 76: 664-666
53. Mainie I, McGurk C, McClintock G, Robinson J 2001 Seizures after buproprion overdose. Lancet 357: 1624
54. Malesker MA, Soori GS, Malone PM, Mahowald JA, Housel GJ 1995 Eosinophilia associated with bupropion. Ann Pharmacother 29: 867-869
55. Masand P, Stern TA 1993 Bupropion and secondary mania. Is there a relationship? Ann Clin Psychiatry 5: 271-274
56. McRobbie H, Aaserud E, Lefrandt JD, Pilger E, Astbury C, Hider AESR 2002 Zyban is an effective and well tolerated aid to smoking cessation in smokers with cardiovascular disease: an international study. Nicotine Tobacco Res 4: 237
57. Medicines Control Agency 2002 Zyban (bupropion hydrochloride) - safety update. MCA Medicines Control Agency, www.mca.gov.uk.
58. Mendels J, Amin MM, Chouinard G, Cooper AJ, Miles JE, Remick RA et al 1983 A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry 44: 118-120
59. Miller L, Griffith J 1983 A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology (Berl) 80: 199-205
60. Musso DL, Mehta NB, Soroko FE, Ferris RM, Hollingsworth EB, Kenney BT 1993 Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion. Chirality 5: 495-500
61. Oslin DW, Duffy K 1993 The rise of serum amino-transferases in a patient treated with bupropion. J Clin Psychopharmacol 13: 364-365
62. Peck AW, Bye CE, Clubley M, Henson T, Riddington C 1979 A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br J Clin Pharmacol 7: 469-478
63. Peloso PM, Baillie C 1999 Serum sickness-like reaction with bupropion. JAMA 282: 1817
64. Popli AP, Tanquary J, Lamparella V, Masand PS 1995 Bupropion and anticonvulsant drug interactions. Ann Clin Psychiatry 7: 99-101
65. Posner J, Bye A, Jeal S, Peck AW, Whiteman P 1984 Alcohol and bupropion pharmacokinetics in healthy male volunteers. Eur J Clin Pharmacol 26: 627-630
66. Preskorn SH, Othmer SC 1984 Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy 4: 20-34
67. Puska PMJ, Brath H, Astbury C, Hider AE, Jones S 2002 Bupropion SR (Zyban) is an effective and well-tolerated aid to smoking cessation in a population of healthcare professionals. Nicotine Tobacco Res 4: 237
68. Rigotti NA, Thorndike AN, Durcan MJ, White JD, Niaura R, Gonzales D et al 2001 Attenuation of post-cessation weight gain in smokers taking bupropion: the effect of gender. Nicotine Tobacco Res 2: 304-305
69. Rush CR, Kollins SH, Pazzaglia PJ 1999 Discriminative stimulus and participant-rated effects of methylphenidate, bupropion and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol 6: 32-44
70. Santiago Hernando ML, Roldan SJ, Gutierrez AA, Munoz GB 2002 Serum sickness-like reaction induced by bupropion. (Enfermedad del suero-like asociada a bupropion.) Med Clin (Barc) 119: 76
71. Schroeder DH 1983 Metabolism and kinetics of bupropion. J Clin Psychiatry 44: 79-81
72. Shad MU, Preskorn SH 1997 A possible bupropion and imipramine interaction. J Clin Psychopharmacol 17: 118-119
73. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA et al 2000 The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148: 33-40
74. Silagy C, Mant D, Fowler G, Lancaster T 2000 Nicotine replacement therapy for smoking cessation. Cochrane Database Syst RevCD000146
75. Slemmer JE, Martin BR, Damaj MI 2000 Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295: 321-327
76. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M et al 2001 Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet 357: 1571-1575
77. Tekle A, al Khamis KI 1990 Phenytoin-bupropion interaction: effect on plasma phenytoin concentration in the rat. J Pharm Pharmacol 42: 799-801
78. Tella SR, Ladenheim B, Cadet JL 1997 Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther 281: 508-513
79. Tonstad S 2002 Use of sustained-release bupropion in specific patient populations for smoking cessation. Drugs 62 (Suppl 2): 37-43
80. Tripathi A, Greenberger PA 1999 Bupropion hydrochloride induced serum sickness-like reaction. Ann Allergy Asthma Immunol 83: 165-166
81. Vassout A, Bruinink A, Krauss J, Waldmeier P, Bischoff S 1993 Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants. J Recept Res 13: 341-354
82. Velicer WF, Prochaska JO, Rossi JS, Snow MG 1992 Assessing outcome in smoking cessation studies. Psychol Bull 111: 23-41
83. Warner KE 1997 Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence and implications for coverage. Pharmacoeconomics 11: 538-549
84. Yolles JC, Armenta WA, Alao AO 1999 Serum sickness induced by bupropion. Ann Pharmacother 33: 931-933